Large Pharma Meets Longevity: Gero’s Blueprint for Strategic Partnerships

Session details:

Session overview:

Longevity is emerging as one of the most ambitious frontiers in healthcare, and large pharmaceutical companies are beginning to take notice. This session explores how AI-driven insights are helping bridge the gap between longevity science and drug development, enabling meaningful partnerships between biotechs and pharma.

Through the lens of Gero’s collaborations with Pfizer and Chugai Pharmaceutical, attendees will learn how a data-first approach to human aging biology can unlock new therapeutic opportunities and reshape how the industry views aging and age-related diseases.

Key takeaways:

• How Gero’s AI platform identifies targets that connect longevity biology to drug discovery
• What’s driving large pharma’s growing interest in the longevity space
• Lessons from Gero’s Pfizer and Chugai partnerships on building scalable, science-led collaborations